Physician profile
Johannes Benjamin Pulst-Korenberg
NPI 1558772368
$12,040.52
in general payments reported to CMS, 2019-2025
8 companies · $2,021 in 2025
The $2,021 reported for 2025 was more than what 90% of Neurocritical Care providers received nationally (typical 2025 total: $95.82).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $234 · 2023: $108 · 2024: $9,678 · 2025: $2,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,420 · Food and Beverage: $1,342 · Travel and Lodging: $1,000 · Education: $44.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,420.00 |
| Food and Beverage | $1,341.94 |
| Travel and Lodging | $999.89 |
| Education | $44.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $9,035.97 | 2024 | Uplizna |
| Alexion Pharmaceuticals, INC. | $2,283.26 | 2024-2025 | Strensiq, Soliris, Ultomiris |
| Novartis Pharmaceuticals Corporation | $260.61 | 2021-2024 | |
| Tg Therapeutics, INC. | $156.60 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $109.09 | 2021 | |
| Biogen, INC. | $39.07 | 2024 | Tysabri, Vumerity |
| Emd Serono, INC. | $30.92 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johannes Pulst-Korenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.